Trial
NCT04458909
Testing the Addition of an Anti-cancer Immune Therapy Drug (Nivolumab) to the Usual Chemotherapy Treatment (Cisplatin or Carboplatin With Gemcitabine) for Recurrent or Metastatic Nasopharyngeal Cancer
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
National Cancer Institute (NCI)
Collaborators
NRG Oncology
Condition
Metastatic Nasopharyngeal Carcinoma
Intervention
Carboplatin
Why stopped
External information
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-10-03